Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00139841 | Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab | completed | Phase 3 | 103 | CephalonINDUSTRY | 3 | May 9, 2014 | clinicaltrials |
| NCT00507416 | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone(UPFRONT) | completed | Phase 3 | 502 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | May 1, 2014 |
| clinicaltrials |
| NCT00215943 | Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | terminated | Phase 3 | 90 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 2 | Apr 17, 2014 | clinicaltrials |
| NCT00103610 | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients | completed | Phase 3 | 298 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Mar 13, 2014 | clinicaltrials |
| NCT00103662 | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients | completed | Phase 3 | 302 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Mar 13, 2014 | clinicaltrials |
| NCT00218855 | Thalidomide to Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | 363 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT02024815 | Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. | unknown | Phase 3 | 100 | Lithuanian University of Health SciencesOTHER | 1 | Dec 31, 2013 | clinicaltrials |
| NCT01998503 | Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | completed | Phase 3 | 56 | Nanjing University School of MedicineOTHER | 1 | Nov 29, 2013 | clinicaltrials |
| NCT00205751 | Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy | completed | Phase 2 / Phase 3 | 350 | Austrian Forum Against CancerOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00205764 | Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy | completed | Phase 3 | 212 | Austrian Forum Against CancerOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01355783 | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma | withdrawn | Phase 3 | 0 | Eisai Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT01110824 | Prevention of Left Ventricular Dysfunction During Chemotherapy(OVERCOME) | completed | Phase 3 | 90 | Hospital Clinic of BarcelonaOTHER | 1 | Nov 15, 2013 | clinicaltrials |
| NCT00934154 | Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma | completed | Phase 3 | 122 | Cigdem Sahinbas YILMAZINDUSTRY | 1 | Aug 15, 2013 | clinicaltrials |
| NCT00480363 | QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression(QUIREDEX) | completed | Phase 3 | 120 | PETHEMA FoundationOTHER | 1 | Jul 31, 2013 | clinicaltrials |
| NCT00352846 | Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss | completed | Phase 3 | 135 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00090493 | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma | completed | Phase 2 / Phase 3 | 4 | University of ArkansasOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00002556 | Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | completed | Phase 3 | 312 | National Cancer Institute (NCI)NIH | 1 | May 31, 2013 | clinicaltrials |
| NCT01801436 | A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma | completed | Phase 3 | 14 | Johnson & Johnson Taiwan LtdINDUSTRY | 0 | May 16, 2013 | clinicaltrials |
| NCT01188798 | Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies | completed | Phase 3 | 6 | St. Jude Children's Research HospitalOTHER | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00002649 | Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 3 | 206 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00003204 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 3 | 515 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01266811 | A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 3 | 0 | Centocor, Inc.INDUSTRY | 14 | Jan 28, 2013 | clinicaltrials |
| NCT00209222 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | unknown | Phase 3 | 360 | European Mantle Cell Lymphoma NetworkOTHER | 3 | Sep 10, 2012 | clinicaltrials |
| NCT01570049 | Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma | unknown | Phase 3 | 100 | Shandong Lanjin Pharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 2, 2012 | clinicaltrials |
| NCT01103388 | Rituximab Maintenance After Autologous Transplantation | terminated | Phase 3 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT00127881 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | terminated | Phase 3 | 76 | Emergent Product Development Seattle LLCINDUSTRY | 5 | Jul 26, 2012 | clinicaltrials |
| NCT01134484 | VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) | unknown | Phase 3 | 480 | Michele CavoOTHER | 1 | Jul 20, 2012 | clinicaltrials |
| NCT00463463 | Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma(Zevalin) | unknown | Phase 3 | — | Soroka University Medical CenterOTHER | 1 | Jul 12, 2012 | clinicaltrials |
| NCT00312845 | Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | completed | Phase 3 | 676 | Millennium Pharmaceuticals, Inc.INDUSTRY | 32 | Jun 25, 2012 | clinicaltrials |
| NCT00998270 | Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma | unknown | Phase 2 / Phase 3 | 185 | Tehran University of Medical SciencesOTHER | 1 | Jun 4, 2012 | clinicaltrials |
| NCT00420849 | A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 587 | Celgene CorporationINDUSTRY | 5 | May 21, 2012 | clinicaltrials |
| NCT00725231 | Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP(A-CHOP-14) | unknown | Phase 3 | 274 | University of GöttingenOTHER | 1 | May 7, 2012 | clinicaltrials |
| NCT00171925 | Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I | terminated | Phase 3 | 143 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT01532856 | Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years | unknown | Phase 3 | 64 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00091676 | Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma(BiovaxID) | unknown | Phase 3 | 629 | Biovest InternationalINDUSTRY | 0 | Feb 3, 2012 | clinicaltrials |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 620 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 | completed | Phase 3 | 600 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00478777 | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 150 | Celgene CorporationINDUSTRY | 1 | Nov 3, 2011 | clinicaltrials |
| NCT01459887 | Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma | completed | Phase 3 | 278 | Shanghai CP Guojian Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 26, 2011 | clinicaltrials |
| NCT00722566 | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 222 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Oct 10, 2011 | clinicaltrials |
| NCT00443235 | GEM05 for Patients With Multiple Myeloma More Than 65 Years Old | completed | Phase 3 | 260 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00573391 | Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 | terminated | Phase 3 | 5 | University of ArkansasOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00816959 | Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma | unknown | Phase 3 | 1,200 | American Scitech InternationalOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00546780 | A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse(BMS TIME-1) | completed | Phase 3 | 31 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 28, 2011 | clinicaltrials |
| NCT00846157 | Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients(NKCell) | unknown | Phase 3 | 276 | NKBio Co.Ltd.INDUSTRY | 1 | Jun 28, 2011 | clinicaltrials |
| NCT00344422 | Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 198 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jun 10, 2011 | clinicaltrials |
| NCT00261677 | A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy | completed | Phase 3 | 224 | Ortho Biotech Products, L.P.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00270101 | The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | completed | Phase 3 | 156 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
Data updated 22 days agoSource updated May 9, 2014source: clinicaltrials